Matching articles for "hot flashes"
Issue 1697 · March 4, 2024
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent…

Med Lett Drugs Ther. 2024 Mar 4; 66(1697):33-8 doi:10.58347/tml.2024.1697a
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Issue 1679 · June 26, 2023
Fezolinetant (Veozah) for Menopausal Vasomotor Symptoms

Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):97-9 doi:10.58347/tml.2023.1679a
Fezolinetant ( Veozah – Astellas), a first-in-class neurokinin 3 (NK3) receptor antagonist, has been approved by the FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. It is the second nonhormonal treatment to be approved in the US for this indication; a low-dose formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate (Brisdelle) was approved in 2013.
Issue 1604 · August 10, 2020
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and…

Med Lett Drugs Ther. 2020 Aug 10; 62(1604):124-8
The primary symptoms of menopause are genitourinary (genitourinary syndrome of menopause; GSM) and vasomotor (VMS). Vulvovaginal atrophy can cause vaginal burning, irritation and dryness, dyspareunia, and dysuria, and increase the risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep. Hormone therapy is the most effective treatment for both genitourinary and vasomotor symptoms.
Issue 1577 · July 29, 2019 Free
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

In our article on Bijuva , the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99) , Table 1 should have included single-ingredient oral formulations of estradiol and…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):120
In our article on Bijuva , the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99) , Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone ( Provera , and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva , but they cost less and allow for more dosing flexibility.
Issue 1575 · July 1, 2019
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an…

Med Lett Drugs Ther. 2019 Jul 1; 61(1575):99-101
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Issue 1566 · February 25, 2019
Oxybutynin for Hot Flashes in Women with Breast Cancer

Interim results of a double-blind, placebo-controlled trial suggest that off-label use of the anticholinergic drug oxybutynin may reduce the frequency and severity of hot flashes in women with breast cancer.…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):30-1
Interim results of a double-blind, placebo-controlled trial suggest that off-label use of the anticholinergic drug oxybutynin may reduce the frequency and severity of hot flashes in women with breast cancer. Extended-release oral oxybutynin ( Ditropan XL , and generics) has been shown to reduce the frequency and severity of hot flashes in healthy menopausal women.
Issue 1314 · June 15, 2009 Free
In Brief: Tamoxifen and SSRI Interactions

Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen ( Nolvadex , and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen…

Med Lett Drugs Ther. 2009 Jun 15; 51(1314):45-6
Use of a selective serotonin reuptake inhibitor (SSRI) is common in women taking tamoxifen ( Nolvadex , and others) for breast cancer, both to treat depression and to decrease hot flashes. However, tamoxifen must be metabolized by CYP2D6 to become pharmacologically fully active (MJ Higgins et al. J Natl Compr Canc Netw 2009; 7:203) , and the SSRIs fluoxetine ( Prozac , and others) and paroxetine ( Paxil , and others) are strong inhibitors of CYP2D6. Sertraline ( Zoloft , and others) inhibits CYP2D6 to a lesser extent. Citalopram ( Celexa , and others) and escitalopram (Lexapro) , the 2 other SSRIs approved for treatment of depression, are only weak inhibitors of CYP2D6. Two observational studies presented at a recent meeting of the American Society of Clinical Oncology (45th annual meeting, May 29-June 2, 2009, Orlando, FL abstracts CRA508, CRA509) examined the effect of strong inhibitors of CYP2D6 on the success rate of tamoxifen in preventing recurrence of breast cancer. One found that women who took fluoxetine, paroxetine or sertraline (or bupropion, duloxetine, terbinafine, quinidine or long-term diphenhydramine) with tamoxifen had a higher 2-year recurrence rate (13.9% vs. 7.5%). The other study found no association between cancer recurrence and use of a CYP2D6 inhibitor. There is no good evidence that any one SSRI is more effective than any other for treatment of depression. For women who are taking tamoxifen and need to begin treatment with an SSRI to treat depression, citalopram or escitalopram might be the safest choice (Treat Guidel Med Lett 2006; 4:35) . Use of an SSRI to treat hot flashes in women taking tamoxifen should probably be reconsidered. Download: U.S. English
Issue 1197 · December 6, 2004
Treatment of Menopausal Vasomotor Symptoms

Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were…

Med Lett Drugs Ther. 2004 Dec 6; 46(1197):98-9
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?